ATE140482T1 - Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz - Google Patents

Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz

Info

Publication number
ATE140482T1
ATE140482T1 AT93910848T AT93910848T ATE140482T1 AT E140482 T1 ATE140482 T1 AT E140482T1 AT 93910848 T AT93910848 T AT 93910848T AT 93910848 T AT93910848 T AT 93910848T AT E140482 T1 ATE140482 T1 AT E140482T1
Authority
AT
Austria
Prior art keywords
egs
rna
rnaase
cleavage
loop
Prior art date
Application number
AT93910848T
Other languages
English (en)
Inventor
Yan Yuan
Cecilia L Guerrier-Takada
Sidney Altman
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE140482T1 publication Critical patent/ATE140482T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93910848T 1992-04-28 1993-04-28 Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz ATE140482T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87509992A 1992-04-28 1992-04-28
US93193792A 1992-08-18 1992-08-18

Publications (1)

Publication Number Publication Date
ATE140482T1 true ATE140482T1 (de) 1996-08-15

Family

ID=27128368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910848T ATE140482T1 (de) 1992-04-28 1993-04-28 Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz

Country Status (10)

Country Link
EP (1) EP0638121B1 (de)
JP (1) JP3015463B2 (de)
AT (1) ATE140482T1 (de)
AU (1) AU669367B2 (de)
CA (1) CA2117903C (de)
DE (1) DE69303712T2 (de)
DK (1) DK0638121T3 (de)
ES (1) ES2093427T3 (de)
GR (1) GR3020859T3 (de)
WO (1) WO1993022434A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
AU732321B2 (en) * 1997-11-21 2001-04-12 Yale University Method for identifying and inhibiting functional nucleic acid molecules in cells
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
KR20040096554A (ko) 2002-02-06 2004-11-16 비코르 테크놀로지스 인코포레이티드 경색방지 분자
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
EP1766013B1 (de) 2004-04-29 2011-06-08 Yale University Nukleaseresistente externe führungssequenzen zur behandlung von entzündlichen und virusbedingten atemwegserkrankungen
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2392646A1 (de) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US9365622B2 (en) 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2664189C (en) 2006-09-21 2017-11-21 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9241898B2 (en) 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
EP2288922B1 (de) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
US20110318738A1 (en) 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
US20120077753A1 (en) 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110274745A1 (en) 2009-11-10 2011-11-10 Lipella Pharmaceuticals Inc. Instillation of liposomal formulation of sirna and antisense oligonucleotides
US8889615B2 (en) 2009-12-31 2014-11-18 New York University Methods for promoting epithelialization and healing of chronic wounds
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
CN106177930A (zh) 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
CN107206100B (zh) 2014-10-27 2021-02-12 弗罗里达中央大学研究基金会 自然杀伤细胞的方法和组合物
JP2019524787A (ja) 2016-08-03 2019-09-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｔｌｒ９標的治療薬
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
CN113950525B (zh) * 2021-01-27 2022-06-03 Cj第一制糖株式会社 新型核糖核酸酶p变体及使用其生产l-谷氨酸的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2750127B2 (ja) * 1988-07-29 1998-05-13 三共株式会社 リボザイムによるポリリボヌクレオチド特定部位の切断方法
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P

Also Published As

Publication number Publication date
GR3020859T3 (en) 1996-11-30
DK0638121T3 (da) 1996-08-12
WO1993022434A3 (en) 1993-12-23
CA2117903A1 (en) 1993-11-11
AU669367B2 (en) 1996-06-06
EP0638121B1 (de) 1996-07-17
DE69303712D1 (de) 1996-08-22
DE69303712T2 (de) 1997-02-20
JPH07507683A (ja) 1995-08-31
EP0638121A1 (de) 1995-02-15
CA2117903C (en) 1999-01-12
ES2093427T3 (es) 1996-12-16
AU4119893A (en) 1993-11-29
WO1993022434A2 (en) 1993-11-11
JP3015463B2 (ja) 2000-03-06

Similar Documents

Publication Publication Date Title
ATE140482T1 (de) Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
CY1112430T1 (el) Λεντινοϊικο τριπλο dνα και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dνα
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
ES2155702T4 (es) Construcciones expresivas halteroformes para la terapia genetica.
EP0484374A4 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
EP0677056A1 (de) Olionukleotidalkylphosphonate und -phosphonothioate.
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
SG141233A1 (en) Control of gene expression
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
LT2001062A (en) Device for facilitating the implantation of biological material
ATE397461T1 (de) Auf tgf-beta 1 ansprechende knochenmarkzellen
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
KR930701610A (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
WO2002050111A3 (en) Isolated laminin 10
DE3773512D1 (de) Vektor und verfahren zur erreichung einer hohen expression in zellen.
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
SE9804298D0 (sv) New medical use
JPS6480281A (en) Plant cell and body
Rogers et al. Unstable high molecular weight inverted repetitive DNA in human lymphocytes
Yuan et al. Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee